Hormonal therapy with letrozole prior to surgical management of recurrent metastatic low-grade endometrial stromal sarcoma (LGESS)

Tzakas, Elias; Liu, S; Todd, Richard W.; Redman, C. W. E.

doi:10.3109/01443610903165552

Cited by 15 publications

(6 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Up to 63% of uterine sarcomas exhibit ER expression. 2 Aromatase inhibitors, progesterone, and gonadotropin-releasing hormone agonists have been suggested treatments of uterine sarcomas, especially ESS 1,9,19,20 and possibly LMS. 2 Progesterone has been the most widely used and accepted adjuvant therapy for ESS, 9,19 with multiple retrospective studies showing benefit as both adjuvant and recurrent therapy.…”

mentioning

confidence: 99%

“…8,21Y24 Although progesterone is an effective medication, it has a variety of adverse effects including hot flashes, weight gain, water retention, and prothrombotic effects. 19 Aromatase inhibitors are better tolerated and seem to be a good option for the adjuvant treatment of ESS 1,2,9,19,20 or as a second-line treatment in patients who fail a trial of progesterone. 2,8,20,25 On the basis of the toxicity profile of AIs combined with several favorable case reports, some authors believe that AIs should be considered the standard of care for certain uterine sarcomas.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Uterine Sarcoma and Aromatase Inhibitors: Tom Baker Cancer Centre Experience and Review of the Literature

Altman

Nelson

Chu

et al. 2012

Int J Gynecol Cancer

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

mentioning

confidence: 99%

Uterine Sarcoma and Aromatase Inhibitors: Tom Baker Cancer Centre Experience and Review of the Literature

Altman

Nelson

Chu

et al. 2012

Int J Gynecol Cancer

View full text Add to dashboard Cite

show abstract

“…Therefore, it is not clear if lung metastasis is associated with a more aggressive course or with durable responses to aromatase inhibitors. In the reported literature we identified a few cases with lung metastasis treated with letrozole (Table 1) [6][7][8][9][10][11][12][13][14][15][16][17][18][19].…”

Section: Discussionmentioning

confidence: 99%

Durable Response to Letrozole in a Patient with Relapsed Low Grade Endometrial Stromal Sarcoma Metastatic to the Lung - A Case Report

Salah¹,

Saleh²,

Zmaily³

et al. 2019

Med Case Rep

View full text Add to dashboard Cite

Low Grade Endometrial Stromal Sarcomas (LGESS) are rare uterine neoplasms, with high propensity for local recurrence and an indolent course. Distant metastasis is rare. Hormonal therapy with progestin or aromatase inhibitors has been used successfully to treat relapsed and unresectable disease. We report a 55-year-old female patient with relapsed LGESS in the lungs, who achieved almost complete response to letrozole for more than 6 years. To our knowledge, this is the longest reported durable response with letrozole in patients with LGESS and lung metastasis.

show abstract

“…In unresectable disease, endocrine therapy is thought to be the treatment of choice since ESS is considered to be relatively radio-and chemo-therapy resistant. Under hormonal therapy, partial response (PR) or disease stabilization (SD) of ESS le- [7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24]. AIs were used as first-line or second-line (or later-line) treatment, salvage after prior chemotherapy or adjuvant therapy after complete resection of the metastatic lesions.…”

Section: Discussionmentioning

confidence: 99%

Aromatase inhibitor therapy for endometrial stromal sarcoma — two-centre experience

et al. 2018

View full text Add to dashboard Cite

Objectives: Endocrine therapy is the recommended systemic treatment for steroid receptor positive endometrial stromal sarcoma (ESS). There is no current consensus on the optimal hormonal therapy for ESS. The literature offers several reports on advanced/recurrent/metastatic ESS patients treated with progestins, whereas data on the efficacy of aromatase inhibitors are scarce. Material and methods: We retrospectively identified cases treated for ESS with aromatase inhibitors at our institutions. There were five patients with advanced or unresectable recurrent estrogen, progesterone and androgen receptor-positive ESS, treated with aromatase inhibitors: letrozole or anastrozole (at a daily dose of 2.5 mg and 1 mg, respectively), as first-line endocrine therapy in all but one case treated following progression with megestrol acetate. Results: Disease stabilization was achieved in four cases (80%), including two with long-term progression-free survival for up to 10 years attained under letrozole treatment, and one case after prior progestin treatment. During therapy, no substantial toxicity was observed. Conclusions: Aromatase inhibitors as first-or second-line endocrine treatment achieve disease control in most steroid receptor positive ESS. Our series of cases is evidence of aromatase inhibitors efficacy as long-term endocrine treatment option for ESS patients.

show abstract

Hormonal therapy with letrozole prior to surgical management of recurrent metastatic low-grade endometrial stromal sarcoma (LGESS)

Cited by 15 publications

References 11 publications

Uterine Sarcoma and Aromatase Inhibitors: Tom Baker Cancer Centre Experience and Review of the Literature

Uterine Sarcoma and Aromatase Inhibitors: Tom Baker Cancer Centre Experience and Review of the Literature

Durable Response to Letrozole in a Patient with Relapsed Low Grade Endometrial Stromal Sarcoma Metastatic to the Lung - A Case Report

Aromatase inhibitor therapy for endometrial stromal sarcoma — two-centre experience

Contact Info

Product

Resources

About